Country data on AMR in Mexico in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome

被引:2
作者
Torumkuney, Didem [1 ]
de la Torre, Carlos [2 ]
Langfeld, Karen [1 ]
Lopez-Turrent, Norma Patricia [3 ]
Beltrame, Cristiana Ossaille [4 ]
机构
[1] GlaxoSmithKline, 980 Great West Rd, Brentford TW8 9GS, Middx, England
[2] Hosp Infantil Mexico Dr Federico Gomez, Dept Paediat Otolaryngol, Mexico City, DF, Mexico
[3] GlaxoSmithKline, Torre Mitikah Piso 19 & 20, Mexico City 03330, DF, Mexico
[4] GlaxoSmithKline, Estr Bandeirantes 8464, BR-22783110 Jacarepagua, RJ, Brazil
关键词
DISEASES-SOCIETY; THORACIC-SOCIETY; PNEUMONIA; MANAGEMENT; DIAGNOSIS; ADULTS;
D O I
10.1093/jac/dkac216
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action. Objectives: To review AMR in Mexico and initiatives addressing it. Identifying any areas where more information is required will provide a call to action to minimize any further rises in AMR and to improve patient outcomes. Methods: National AMR initiatives in Mexico, antibiotic use and prescribing, and availability of susceptibility data, particularly the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines commonly used in Mexico for specific CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) were also reviewed, along with local antibiotic availability. Insights from a local clinician were sought to contextualize this information. Conclusions: The Mexican national AMR strategy was published in 2018. This comprised similar objectives to the Global Action Plan from the World Health Assembly (2015) and was compulsory, requiring full compliance from members of the National Health System. Historically, antibiotic consumption in Mexico has been high, however, between 2000 and 2015, consumption fell, in sharp contrast to the majority of countries. Mexico lacks a national surveillance network for AMR, however there are several ongoing global surveillance studies providing local antibiotic susceptibility data. International and local antibiotic prescribing guidelines for CA-RTIs are used. A more standardized inclusive approach in developing local guidelines, using up-to-date local surveillance data of isolates from community-acquired infections, could make guideline use more locally relevant. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development in Mexico and improve patient outcomes.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 44 条
  • [1] Antibiotic usage and resistance in Mexico: an update after a decade of change
    Amabile-Cuevas, Carlos F.
    [J]. JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2021, 15 (04): : 442 - 449
  • [2] [Anonymous], 2015, ACTUALIZACION
  • [3] [Anonymous], Substandard and Falsified Medical Products
  • [4] [Anonymous], 2020, WHO Antibiotic resistance
  • [5] [Anonymous], 2015, GLOB ACT PLAN ANT RE, V10, P354, DOI DOI 10.1128/MICROBE.10.354.1
  • [6] [Anonymous], 2021, Global Antimicrobial Resistance and Use Surveillance System (GLASS)
  • [7] Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence
    Ball, P
    Baquero, F
    Cars, O
    File, T
    Garau, J
    Klugman, K
    Low, DE
    Rubinstein, E
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) : 31 - 40
  • [8] Ciprofloxacin-Induced Psychosis
    Ben-Chetrit, Eli
    Rothstein, Neil
    Munter, Gabriel
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (08) : 4079 - 4079
  • [9] Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]
  • [10] Canton R., 2022, J ANTIMICROBIAL CHEM, V77